ArticleCancer immunology research2018
IL22 Promotes
Open access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 69 citations in OpenAlex.
- Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.Stem cell reviews and reports · 2026Review
- Contextualizing TNature reviews. Immunology · 2026Review
- Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025Review
- Investigating causal relationships between plasma proteins and lung adenocarcinoma: result from proteomics and Mendelian randomization study.Discover oncology · 2025Article
- Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity.Frontiers in immunology · 2025Article
- Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer.Cancer medicine · 2024Article
- IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.Heliyon · 2024Review
- The role of IL-22 in cancer.Medical oncology (Northwood, London, England) · 2024Review
- IL20RB signaling enhances stemness and chemotherapy resistance in pancreatic cancer.Journal of translational medicine · 2023Article
- Review
- T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.Immunity · 2023Article
- Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22.Immunity · 2023Article
- Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.Frontiers in immunology · 2023Review
- Article
- Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.Nature communications · 2022Article
- Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.JCI insight · 2022Article
- Cell Type-Specific Roles of STAT3 Signaling in the Pathogenesis and Progression of K-ras Mutant Lung Adenocarcinoma.Cancers · 2022Review
- Biological characteristics of γδT cells and application in tumor immunotherapy.Frontiers in genetics · 2022Review
- TargetingFrontiers in oncology · 2022Review
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
Corrections and comments
- Commented on by
Authors and funding
19 authors at 2 institutions in 4 countries.
Nasim KhosraviDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mauricio S CaetanoDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amber M CumpianDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nese UnverDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cynthia De la Garza RamosTecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, México.
Oscar NobleTecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo León, México.
Soudabeh DaliriDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Belinda J HernandezDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Berenice A GutierrezDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Scott E EvansDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Samir HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Andrei M AlekseevDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yi YangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Seon Hee ChangDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Roza NurievaDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Humam KadaraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jichao ChenDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Edwin J OstrinDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Seyed Javad MoghaddamDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. smoghadd@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Monterrey · MX
Funding
Role of AT1 cells in perinatal lung maturationR01HL130129 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, JICHAO · 2016 to 2023
$4.1MEpithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M(PQ1) Progression of the airway field of injury to Kras mutant lung cancerR01CA205608 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KADARA, HUMAM, SCHEET, PAUL A · 2016 to 2019
$1.4MSTAT1: New regulator of inflammatory Th17 and Th2 cellsR21AI120012 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2016 to 2017
$440kRole of Cul4A in Th2 tolerance and airway inflammationR56AI125269 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2017 to 2017
$300kGrail-targeting breaks the immune tolerance to melanomaR03CA219760 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2017 to 2018
$160kNCI NIH HHS R01 CA205608NCI NIH HHS R03 CA219760NHLBI NIH HHS R01 HL117976NHLBI NIH HHS R01 HL130129NIAID NIH HHS R21 AI120012NIAID NIH HHS R56 AI125269
Abstract
Somatic
Indexed as
MutationAnimalsAnimals, Genetically ModifiedCell Transformation, NeoplasticDisease Models, AnimalGene ExpressionHumansImmunohistochemistryInterleukin-22InterleukinsLung NeoplasmsMiceNeoplastic Stem CellsProto-Oncogene Proteins p21(ras)Signal TransductionSTAT3 Transcription FactorInterleukin-22InterleukinsKRAS protein, humanProto-Oncogene Proteins p21(ras)STAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.